Eli Lilly's weight loss drug Zepbound is now available at US pharmacies
Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US, sending its shares slightly higher Tuesday. The treatment is expected to cost $25...
No more exercising? President RFK Jr.?
Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will...
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug ma...
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the ...
3 No-Brainer Growth Stocks to Buy in December
Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity ...
US FDA gives second approval to Eli Lilly's drug for type of blood cancer
Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer.
There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term,...
1 Underrated Reason to Buy Eli Lilly Stock
The shares have vaulted as a result of its recently approved weight-loss drug. But it also pays a dividend, which has increased steadily over the years.
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
Some leading U.S. obesity specialists say they expect Eli Lilly's powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk's popular Wegovy as they belong ...
Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program
Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to ather...
How to earn $500 a month from this stock?
Pfizer's (NASDAQ: PFE) stock continued its 11-month decline in November after its third-quarter sales missed expectations amid waning demand for Covid products.
Arecor extends its relationship with Lilly as it inks another technology deal
Arecor Therapeutics PLC (AIM:AREC) announces an expanded collaboration with Eli Lilly and Company that will see the former's Arestat technology use to develop a new enhanced liquid formulation of a...
Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) 6th Evercore ISI HealthCONx Conference November 28, 2023 3:50 PM ET Company Participants Dan Skovronsky - EVP, Chief Scientific and Medical Officer Conference Call...
3 Large Drug Stocks That Have Outperformed Industry YTD
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
Related Companies